Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality

Medicina Clinica

Volumn 138, Issue 15, 2012, Pages 650-655

  Hernández Torres, Alicia ^a   García Vázquez, Elisa ^a,b   Gómez, Joaquín ^a,b   Canteras, Manuel ^b   Ruiz, Joaquín ^a   Yagüe, Genoveva ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Acinetobacter baumannii; Infection; Mortality; Multidrug resistant; Treatment

Indexed keywords

AMIKACIN; CARBAPENEM; COLISTIMETHATE; RIFAMPICIN; SULBACTAM; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HOSPITAL LABORATORY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

EID: 84860719695     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2011.06.024     Document Type: Article

References (33)

1. R.H. Sunenshine, M.O. Wright, L.L. Maragakis, A.D. Harris, X. Song, and J. Hebden Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization Emerg Infect Dis 13 2007 97 103
2. M.E. Falagas, P. Kopterides, and I.I. Siempos Attributable mortality of Acinetobacter baumannii infection among critically ill patients Clin Infect Dis 43 2006 389 390
3. A.Y. Peleg, H. Seifert, and D.L. Paterson Acinetobacter baumannii: emergence of a successful pathogen Clin Microbiol Rev 21 2008 538 582
4. E. Gkrania-Klotsas, and R.C. Hershow Colonization or infection with multidrug-resistant Acinetobacter baumannii may be an independent risk factor for increased mortality Clin Infect Dis 43 2006 1224 1225
5. H.P. Chen, T.L. Chen, Lai ChH, C.P. Fung, W.W. Wong, and K.W. Yu Predictors of mortality in Acinetobacter baumannii bacteremia J Microbiol Immunol Infect 38 2005 127 136
6. A. Hernández-Torres, E. García-Vázquez, J. Gómez, M. Canteras, J. Ruiz, and A. Fernández-Rufete Carbapenem and multidrug resistant A. baumannii colonisation/infection: epidemiology and factors associated with infection Med Clin 135 2010 389 396
7. W.R. McCabe Endotoxin and bacteremia due to gram-negative organisms N Engl J Med 283 1970 1342 1343
8. D.J. Winston, W. Murphy, L.S. Young, and W.L. Hewitt Piperacillin therapy for serious bacterial infections Am J Med 69 1980 255 261
9. J.S. Garner, W.R. Jarvis, T.G. Emori, T.C. Horan, and J.M. Hughes CDC definitions for nosocomial infections Am J Infect Control 16 1988 128 140
10. J. Gómez, E. Simarro, V. Baños, L. Requena, J. Ruiz, García, M. Canteras, and M. Valdés Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii Eur J Clin Microbiol Infect Dis 18 1999 358 361
11. D.W. Warcham, D.C. Bean, P. Khanna, E.M. Hennesy, D. Krahe, and A. Ely Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance Eur J Clin Microbiol Infect Dis 27 2008 607 612
12. K.T. Kwon, W.S. Oh, J.H. Song, H.H. Chang, S.I. Jung, and S.W. Kim Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia J Antimicrob Chemother 59 2007 525 530
13. Tseng YCh, J.T. Wang, F.L. Wu, Chen YCh, Chie WCh, and SCh Chang Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii Diagn Microbiol Infect Dis 59 2007 181 190
14. H. Seifert, A. Strate, and G. Pulverer Nosocomial bacteraemia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality Medicine (Baltimore) 74 1995 340 349
15. J.M. Cisneros, and J. Rodríguez-Baño Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment Clin Microbiol Infect 8 2002 687 693
16. M. Dizbay, A. Altuncekic, B.E. Sezer, K. Ozdemir, and D. Arman Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia Int J Antimicrob Agents 32 2008 29 32
17. M.F. Tripodi, E. Durante-Mangoni, R. Fortunato, R. Utili, and R. Zarrilli Comparative activities of colistin, rifampicin, imipenem, and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases Int J Antimicrob Agents 30 2007 537 540
18. J.Y. Song, S.Y. Kee, I.S. Hwang, Y.B. Seo, H.W. Jeong, and W.J. Kim In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J Antimicrob Chemother 60 2007 317 322
19. Lee ChH, Y.F. Tang, L.H. Su, Chien ChCh, and J.W. Liu Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that cause meningitis and bacteremia Microb Drug Resist 14 2008 233 237
20. J.Y. Song, H.J. Cheong, J. Lee, A.K. Sung, and W.J. Kim Efficacy of monotherapy and combined therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model Int J Antimicrob Agents 33 2009 33 39
21. M.E. Pachón-Ibañez, E. Fernández-Cuenca, E. Docobo-Pérez, J. Pachón, and A. Pascual Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam J Antimicrob Chemother 58 2006 689 692
22. S. Motaouakkil, B. Charra, A. Hachimi, H. Nejmi, A. Benslama, and F. Elmdaghri Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii J Infect 53 2006 274 278
23. M. Bassetti, E. Repetto, E. Righi, S. Boni, M. Diverio, and M.P. Molinari Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections J Antimicrob Chemother 61 2008 417 420
24. N. Petrosillo, E. Ioannidou, and M.E. Falagas Colistin monotherapy vs. combination therapy: evidence from microbiological, animal, and clinical studies Clin Microbiol Infect 14 2008 816 827
25. J. Pachón, and J. Vila Treatment of multiresistant Acinetobacetr baumannii infections Curr Opin Investig Drugs 10 2009 150 156
26. N.C. Gordon, and D.W. Wareham A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline J Antimicrob Chemother 63 2009 775 780
27. J.C. Gallagher, and H.M. Rouse Tigecycline for the treatment of Acinetobacter infections: a case series Ann Pharmacother 42 2008 1188 1194
28. J. Vila, and J. Pachón Therapeutic options for Acinetobacter baumannii infections Expert Opin Pharmacother 9 2008 587 599
29. J. Li, C.R. Rayner, R.L. Nation, R.J. Owen, D. Spelman, and K.E. Tan Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 50 2006 2946 2950
30. M.S. Oliveira, G.V. Prado, S.F. Costa, R.S. Grinbaum, and A.S. Levin Ampicillin/sulbactam compared with polymixins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61 2008 1369 1375
31. A.P. Betrosian, F. Farntzeskaki, A. Xanthaki, and E.E. Douzinas Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia J Infect 56 2008 432 436
32. R. Gounden, C. Bamford, R.V. Zyl-Smit, K. Cohen, and G. Maartens Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections BMC Infect Dis 9 2009 1 8
33. M. Catalán, and J.M. Aguado Multiresistant A. baumannii: an universal challenge Med Clin 135 2010 406 407